Middle East And Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size & Outlook, 2026-2034

Middle East And Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Insights

Based on Reed Intelligence findings, the Middle East And Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market size reached USD 142.83 Million in 2025 and is expected to grow to USD 299.74 Million by 2034.
During 2026–2034, the market is forecasted to advance at a CAGR of 8.74%.
Corticosteroids represented the largest share of the Drug Class market in terms of size in 2025.
Among the Drug Class segments, Biologics is forecasted to achieve the highest growth and remain the most lucrative through the forecast period.

Other Key Findings

The global Eosinophilic Granulomatosis with Polyangiitis Treatment Market size saw Middle East And Africa holding a share of 9.85% in 2025.
United States is forecasted to account for the leading share of the global market by 2034.
In Middle East and Africa, United Arab Emirates is forecasted to be the fastest-expanding market, projected to reach USD 126.14 Million by 2034.

Report Summary

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 142.83 Million
Market Size In 2034	USD 299.74 Million
Largest segment	Corticosteroids
Units	Revenue in USD Million
CAGR	8.74% (2026-2034)
Segmnetation Covered
Middle East and Africa	United Arab Emirates Saudi Arabia South Africa Egypt Nigeria Turkey
Drug Class	Corticosteroids Immunosuppressants Biologics
Route of Administration	Oral Injectable
End-Use	Hospitals Specialty Clinics Others
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Middle East And Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Country 2026-2034 (USD Million)

Middle East and Africa	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
United Arab Emirates	XX.x	XX.x	XX.x	57.13	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Saudi Arabia	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
South Africa	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Egypt	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Nigeria	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Turkey	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Middle East And Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Drug Class 2026-2034 (USD Million)

Drug Class	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Corticosteroids	XX.x	XX.x	XX.x	77.3	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Immunosuppressants	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Biologics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Middle East And Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market Route of Administration 2026-2034 (USD Million)

Route of Administration	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Oral	XX.x	XX.x	XX.x	82.9	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Injectable	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Middle East And Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Market End-Use 2026-2034 (USD Million)

End-Use	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospitals	XX.x	XX.x	XX.x	67.6	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Specialty Clinics	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Others	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Author :

Reed Intelligence Research Team

The Reed Intelligence Research Team brings together over 15+ years of collective experience in market research, data analytics, and strategic consulting. Comprising seasoned analysts, economists, and industry specialists, the team delivers precise, data-driven insights across sectors including technology, healthcare, energy, manufacturing, and consumer goods. By combining domain expertise with modern analytical tools, they ensure each report meets the highest standards of accuracy and relevance.